Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

PACLITAXEL 300 MG/50 ML VIAL

Paclitaxel
$1.7700per ML

Strength

6 mg/mL

Manufacturer

Fresenius Kabi USA, LLC

NDC

63323076350

Classification

Generic

Dosage Form

INJECTION, SOLUTION

Route

INTRAVENOUS

Last Updated

1/22/2014

Active Ingredients

PACLITAXEL

Approval Type

Generic (ANDA)

FDA Application

ANDA077574

On Market Since

3/20/2009

Pharmacological Classes

Microtubule Inhibition
Microtubule Inhibitor

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

N/A

Generic Alternatives

1 alternative • Same active ingredient

PACLITAXEL 100 MG/16.7 ML VIAL
Generic
63323076316•Fresenius Kabi USA, LLC
$1.8891
+7% more

Related Drugs

Same classification

GRISEOFULVIN 125 MG/5 ML SUSP
Generic
00472001304•Actavis Pharma, Inc.
$0.2617
per ML
GRISEOFULVIN 125 MG/5 ML SUSP
Generic
62135096841•Chartwell RX LLC
$0.2617
per ML
GRISEOFULVIN 125 MG/5 ML SUSP
Generic
69097036108•Cipla USA Inc.
$0.2617
per ML
GRISEOFULVIN 125 MG/5 ML SUSP
Generic
00713085004•Cosette Pharmaceuticals, Inc.
$0.3348
per ML
PACLITAXEL 300 MG/50 ML VIAL
Generic
61703034250•Hospira Inc.
$1.7700
per ML
PACLITAXEL 100 MG/16.7 ML VIAL
Generic
61703034222•Hospira Inc.
$1.8891
per ML
PACLITAXEL 30 MG/5 ML VIAL
Generic
61703034209•Hospira Inc.
$2.1290
per ML
GRISEOFULVIN ULTRA 125 MG TAB
Generic
00115172401•Amneal Pharmaceuticals of New York LLC
$2.9646
per EA
GRISEOFULVIN ULTRA 125 MG TAB
Generic
00781582701•Sandoz Inc.
$2.9646
per EA
GRISEOFULVIN ULTRA 125 MG TAB
Generic
23155086301•Heritage Pharmaceuticals Inc.
$2.9646
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy